Idiopathic Thrombocytopenic Purpura Market
Number of pages: 100 | Report Format: PDF | Published date: May 02, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
Market Size Value in 2022 |
US$ 651.0 million |
|
Revenue Forecast in 2031 |
US$ 1,036.0 million |
|
CAGR |
5.3% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Class, Distribution Channel, And Region |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, the global idiopathic thrombocytopenic purpura market was valued at US$ 651.0 million in 2022 and is expected to register a revenue CAGR of 5.3% to reach US$ 1,036.0 million by 2031.
Idiopathic Thrombocytopenic Purpura Market Fundamentals
Idiopathic thrombocytopenic purpura, also known as immune thrombocytopenia, is a blood disorder characterized by decreased platelets in the blood. Platelets are blood cells that help the blood to clot and stop bleeding. In people with idiopathic thrombocytopenic purpura, the immune system mistakenly attacks and destroys these platelets, leading to bleeding problems such as bruising, petechiae (small red or purple spots on the skin), nosebleeds, and bleeding gums. Idiopathic thrombocytopenic purpura can affect people of any age, but it is more common in women and children. The disorder can be acute or chronic. Acute idiopathic thrombocytopenic purpura typically develops in children after a viral illness and resolves within a few months. Chronic idiopathic thrombocytopenic purpura can last years and occur in children and adults.
The cause of idiopathic thrombocytopenic purpura is not fully understood, but it is thought to be an autoimmune disorder in which the immune system mistakenly attacks the body's platelets. Other factors, such as medications, infections, and pregnancy, can also trigger idiopathic thrombocytopenic purpura in some cases. Treatment for idiopathic thrombocytopenic purpura depends on the symptoms' severity and the disorder's underlying cause. Mild cases of idiopathic thrombocytopenic purpura may not require treatment. In contrast, more severe cases may require corticosteroids, TPO-RAs, or immunoglobulin therapy to increase platelet counts and prevent bleeding. In some cases, surgery to remove the spleen may be necessary.
[856785]
Idiopathic Thrombocytopenic Purpura Market Dynamics
The incidence and prevalence of idiopathic thrombocytopenic purpura are increasing worldwide, which is the primary driver for the global idiopathic thrombocytopenic purpura market growth. For instance, according to the National Organization for Rare Disorders study of July 2022, adult ITP is expected to affect 3.3 people per 100,000 in the United States each year, with a prevalence of 9.5 per 100,000 people. Developing new and more effective treatment options for idiopathic thrombocytopenic purpura, such as thrombopoietin receptor agonists (TPO-RAs) and immunosuppressants, is fueling the growth of the idiopathic thrombocytopenic purpura market. Additionally, increased awareness about the condition among patients and healthcare providers leads to earlier diagnosis and treatment of ITP, which also drives the demand for idiopathic thrombocytopenic purpura market. Moreover, the increasing healthcare expenditure in developing countries is boosting the growth of the idiopathic thrombocytopenic purpura market. Improved healthcare infrastructure and increased access to healthcare services are expected to contribute to the growth of the idiopathic thrombocytopenic purpura market in the coming years.
However, despite the increasing awareness about idiopathic thrombocytopenic purpura, many cases still go undiagnosed or misdiagnosed. This could lead to a delay in treatment and reduce the demand for idiopathic thrombocytopenic purpura market. Furthermore, idiopathic thrombocytopenic purpura treatments can be prohibitively expensive for many patients, especially in developing countries, where healthcare services are limited. This could limit the growth of the ITP market, particularly in low-income countries. Alternative therapies, such as traditional Chinese medicine and homeopathy, are gaining popularity among patients with idiopathic thrombocytopenic purpura. This could limit the demand for conventional idiopathic thrombocytopenic purpura treatments. Additionally, patent expiration, high cost of treatment, and side effects of treatments are some of the restraints impeding the overall idiopathic thrombocytopenic purpura market growth.
Idiopathic Thrombocytopenic Purpura Market Ecosystem
The global idiopathic thrombocytopenic purpura market is analyzed from three perspectives: drug class, distribution channel, and region.
Idiopathic Thrombocytopenic Purpura Market by Drug Class
[75675]
Based on the drug class, the global idiopathic thrombocytopenic purpura market is segmented into corticosteroids, immunoglobulin, Tpo-RA, and others.
The corticosteroids segment dominated the market with the principal revenue share in 2022. It is one of the oldest and most established drugs and is still widely used as a first-line treatment for patients with idiopathic thrombocytopenic purpura. Corticosteroids are a class of drugs used to treat idiopathic thrombocytopenic purpura (ITP), a medical condition characterized by a low platelet count, which can lead to abnormal bleeding and bruising. They work by suppressing the immune system, reducing the destruction of platelets by the immune system, and increasing the production of platelets. Corticosteroids are relatively inexpensive compared to other idiopathic thrombocytopenic purpura treatments, making them a cost-effective option for patients with idiopathic thrombocytopenic purpura. Developing new formulations of corticosteroids, such as delayed-release formulations, is expected to drive further the growth of corticosteroids in the idiopathic thrombocytopenic purpura market.
The Tpo-Ra segment also accounted for a major share of the market. TPO-RAs, or thrombopoietin receptor agonists, are drugs used to treat idiopathic thrombocytopenic purpura. They work by stimulating the production of platelets in the bone marrow, which can help increase platelet counts in patients with idiopathic thrombocytopenic purpura. TPO-RAs are effective in increasing platelet counts in patients with idiopathic thrombocytopenic purpura. They are often used as a second-line treatment option for patients who do not respond to corticosteroids or immunoglobulin therapy. The development of new TPO-RAs with improved efficacy and safety profiles is expected to drive further the growth of the TPO-RAs segment of the idiopathic thrombocytopenic purpura market.
Idiopathic Thrombocytopenic Purpura Market by Distribution Channel
Based on the distribution channels, the global idiopathic thrombocytopenic purpura market is segmented into hospital pharmacies, retail pharmacies, and online pharmacies.
The hospital segment is a key player in the idiopathic thrombocytopenic purpura market, with the largest revenue share in 2022. Hospital pharmacies are an important segment of the idiopathic thrombocytopenic purpura market, as they play a critical role in providing idiopathic thrombocytopenic purpura treatments to patients in hospital settings. Hospital pharmacies are responsible for dispensing medications, managing drug inventories, and ensuring the safe and effective use of medications in hospital settings. Hospital pharmacies work closely with healthcare providers, including physicians, nurses, and pharmacists, to ensure the safe and effective use of idiopathic thrombocytopenic purpura treatments and improve patient outcomes. These overall factors contribute to the growth of the hospital segment.
The retail pharmacies segment also accounted for a significant share of the market. Retail pharmacies are an important segment of the idiopathic thrombocytopenic purpura market, as they provide a convenient and accessible way for patients to obtain ITP treatments outside hospital settings. Retail pharmacies dispense medications, provide patient education, and offer consultation services to ensure the safe and effective use of medications. These overall factors contribute to the growth of the retail pharmacies segment.
The online pharmacies segment is expected to be the fastest-growing segment throughout the forecast period, attributed to providing patients with an easy and accessible manner to receive prescriptions and manage their disease. Online pharmacies allow patients to order medications and supplies online and have them delivered directly to their homes. Online pharmacies offer a convenient and accessible way for patients to obtain their medications and supplies, especially those living in remote or underserved areas. Compared to traditional pharmacies, online pharmacies frequently offer lower prices on medications and supplies, making them a more cost-effective option for patients. Patients may now get prescriptions and consultations online thanks to the rising use of telemedicine and virtual healthcare services.
Idiopathic Thrombocytopenic Purpura Market by Region
Geographically, the global idiopathic thrombocytopenic purpura market has been segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global idiopathic thrombocytopenic purpura market with the largest revenue share in 2022, attributed to increased access to idiopathic thrombocytopenic purpura treatment, the increased presence of important market competitors upgraded healthcare infrastructure, and expanding awareness of uncommon blood illnesses are all contributing factors. Additionally, companies across the region are continuously involved in partnerships, mergers, and acquisitions to develop new treatment methods, which are also expected to improve the idiopathic thrombocytopenic purpura market outlook. For instance, in March 2023, GAMMAKED is now available at Advanced Infusion Care, a division of AIS Healthcare, for the treatment of patients with primary humoral immunodeficiency (PI), idiopathic thrombocytopenic purpura (ITP) in adults and children, and chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. GAMMAKED is approved to treat PI in patients two years and older, idiopathic thrombocytopenic purpura in adults and children, and CIDP in adults. The treatment approved by the United States Food and Drug Administration in 2011 is currently offered in all AIC sites (Valdosta, Georgia; Birmingham, Alabama; Clinton, Mississippi; Panama City, Florida; and Dallas, Texas).
Idiopathic Thrombocytopenic Purpura Market Competitive Landscape
The prominent players operating in the global idiopathic thrombocytopenic purpura market are:
Idiopathic Thrombocytopenic Purpura Market Strategic Developments
Idiopathic thrombocytopenic purpura, also known as immune thrombocytopenia, is a blood disorder characterized by decreased platelets in the blood.
The global idiopathic thrombocytopenic purpura market was valued at US$ 651.0 million in 2022.
The estimated market size of the global idiopathic thrombocytopenic purpura market in 2031 is US$ 1,036.0 million.
The revenue CAGR of the idiopathic thrombocytopenic purpura market during the forecast period will be 5.3% from 2023 to 2031.
Some prominent players operating in the global idiopathic thrombocytopenic purpura market areGlaxoSmithKline Plc, Amgen Inc., Sun Pharmaceutical Industries Ltd., Hikma Pharmaceuticals PLC, Grifols Biologicals Inc., Intas Pharmaceuticals Ltd., and Rigel Pharmaceuticals, Inc.
*Insights on financial performance are subject to the availability of information in the public domain